Novo Holdings Secures EU Approval for $16.5 Billion Catalent Acquisition
Novo Holdings gains EU approval for its $16.5 billion acquisition of Catalent, a major drug manufacturer. This clears a key hurdle for the deal, expected to close by end of 2024, bolstering Novo’s pharmaceutical capabilities.
Novo Holdings Secures EU Approval for $16.5 Billion Catalent Acquisition Read More »